+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Notch activation as a driver of osteogenic sarcoma



Notch activation as a driver of osteogenic sarcoma



Cancer Cell 26(3): 390-401



Osteogenic sarcoma (OS) is a deadly skeletal malignancy whose cause is unknown. We report here a mouse model of OS based on conditional expression of the intracellular domain of Notch1 (NICD). Expression of the NICD in immature osteoblasts was sufficient to drive the formation of bone tumors, including OS, with complete penetrance. These tumors display features of human OS; namely, histopathology, cytogenetic complexity, and metastatic potential. We show that Notch activation combined with loss of p53 synergistically accelerates OS development in mice, although p53-driven OS is not Rbpj dependent, which demonstrates a dual dominance of the Notch oncogene and p53 mutation in the development of OS. Using this model, we also reveal the osteoblasts as the potential sources of OS.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054662182

Download citation: RISBibTeXText

PMID: 25203324

DOI: 10.1016/j.ccr.2014.07.023


Related references

A Clinico-Anatomical Form of a Rare Osteogenic Sarcoma with Favorable Prognosis: the Juxta-Cortical Osteogenic Sarcoma. Annales Medicales de Nancy 4: 289-293, 1965

Localization of anti-osteogenic sarcoma monoclonal antibody 791T/36 in a primary human osteogenic sarcoma and its subsequent xenograft in immunodeprived mice. Cancer Immunology, ImmunoTherapy 19(1): 18-21, 1985

The toxicity of combination chemo therapy in osteogenic sarcoma within the framework of the cooperative osteogenic sarcoma study. Onkologie 6(5): 268, 1983

In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts. International Journal of Cancer 30(1): 75-85, 1982

Surgical treatment of osteogenic sarcoma in the framework of the cooperative osteogenic sarcoma study in 1981 and 1982. Onkologie 6(5): 267, 1983

Bone scintigraphy in patients with osteogenic sarcoma. Cooperative Osteogenic Sarcoma Study Group COSS 80. Journal of Cancer Research and Clinical Oncology 106 Suppl: 49-50, 1983

Radioimmunoimaging of osteogenic sarcoma xenografts in nude mice using monoclonal antibodies to osteogenic sarcoma. Journal of Nuclear Medicine 26(5): P113-P114, 1985

Study of Osteogenic Sarcoma by Whole Mount Section. 1. Indication for Optimal Level of Amputation in Osteogenic Sarcoma of the Extremity. 2. Histological Evaluation on the Effect of Regional Perfusion of Nitromin-D. Nihon Seikeigeka Gakkai Zasshi 38: 745-767, 1964

Pro-osteogenic topographical cues promote early activation of osteoprogenitor differentiation via enhanced TGF?, Wnt, and Notch signaling. 2013

Clinical picture of osteogenic sarcoma, osteogenic chondrosarcoma and Ewing's sarcoma. Polski Przeglad Chirurgiczny 43(2): 149-154, 1971

Periosteal osteogenic sarcoma an entity distinct from parosteal osteogenic sarcoma. Laboratory Investigation 32(3): 438, 1975

Pro-osteogenic topographical cues promote early activation of osteoprogenitor differentiation via enhanced TGFβ, Wnt, and Notch signaling. Clinical Oral Implants Research 25(4): 475-486, 2015

Naringin Stimulates Osteogenic Differentiation of Rat Bone Marrow Stromal Cells via Activation of the Notch Signaling Pathway. Stem Cells International 2016: 7130653, 2016

Possibilities of adjuvant chemo therapy in osteogenic sarcoma results of the cooperative west german austrian studies cooperative osteogenic sarcoma study. Onkologie 6(5): 269-270, 1983

Extraskeletal Osteogenic Sarcoma : Report of a Case of Osteogenic Sarcoma of the Lip. Annals of Surgery 119(4): 595-601, 1944